CD8A and neoplasm: After genetic modification of human primary CD8+ T‐cell‐derived exosomes, they were impregnated with IL‐2 and cetuximab (CTX), an anti‐EGFR antibody, which has the potential to augment tumor cytotoxicity and refine cancer targeting.376